TOKYO, Feb 5 (Reuters) - Marubeni (8002.T), opens new tab said on Wednesday it is aiming for a net profit of more than 620 billion yen ($4 billion) in fiscal 2027/2028 along with a 40% total ...

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Bone-chilling temperatures couldn’t keep the crowds away from Takeda’s Kendall Square campus on Tuesday to celebrate a milestone for the Japanese drugmaker’s new R&D tower. More than 250 ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. “There's an evolution of our economic model that starts with [the] IRA (Inflation ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker. OSAKA, Japan & CAMBRIDGE, Mass., January 30, 2025--Takeda ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...

Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical (4502.T), opens new tab, is looking to raise $149 million by offering about 7.3 million American depositary shares at $20.34 each.

SYDNEY -- Australia's Queensland state government said on Monday it will halt further investment in a hydrogen project that includes Japanese trading house Marubeni, amid mounting headwinds ...

Takeda has opened an innovation capability centre (ICC) in Bengaluru to leverage the local tech talent pool for building core digital skills. This new centre, part of their Data, Digital ...

In connection with the effectiveness of the agreement, Takeda will make an upfront payment to the Company of $200.0 million. About Keros Therapeutics, Inc. Keros is a clinical-stage ...